BEA-17
Glioblastoma
Pre-clinicalActive
Key Facts
About Beactica Therapeutics
Beactica Therapeutics is an emerging, private biotech transitioning from a service-oriented fragment-based lead generation (FBLG) company to a therapeutics developer with a proprietary pipeline. Its core asset is the Eclipsor™ platform, which integrates allosteric modulation and targeted protein degradation to create novel therapeutics. The company has a validated track record through prior partnerships, has received FDA Orphan Drug Designation for its lead asset BEA-17 in glioblastoma, and is positioned as a 'TPD Company to Watch' with ambitions to become a clinical-stage precision oncology company.
View full company profileTherapeutic Areas
Other Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Ropidoxuridine (IPdR) | Shuttle Pharmaceuticals | Phase 2 |
| LNTH-2505 | Lantheus Medical Imaging | Preclinical |
| Leronlimab | CytoDyn | Preclinical |
| Glioblastoma Moonshot | Owkin | Research |
| OPC-001 (PDC Candidate) | Oncopeptides | Phase 1/Window-of-Opportunity |
| αvβ3-targeted ADC | Xintela | Preclinical |
| Undisclosed | Biossil | Phase 2/3 |
| GLIX1 | Hemispherian | Phase 1 |
| InC01 | InCephalo Therapeutics | Pre-clinical |
| Glioblastoma Combination Therapy | JLP Health | Pre-clinical |
| ENV105 | Kairos Pharma | IND Cleared |
| LMP744 | Gibson Oncology | Phase 2 |